Wang Rui

Mr. Wang Rui


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Medicine
Verified
Journal Article
Open access
WRWang Rui
Wang Rui
XLXia Li
Xia Li
YXYanhan Mm Xu
Yanhan Mm Xu
YLYangyang Mm Li
Yangyang Mm Li
WZWeisong Zhang
Weisong Zhang
SXSong Jian Xiang
Song Jian Xiang
Luteolin (3, 4, 5, 7-tetrahydroxyflavone) are natural flavonoids widely found in vegetables, fruits and herbs, with anti-tumor, anti-inflammatory and antioxidant effects, and also play an anti-cancer effect in various cancers such as lung, breast, prostate, and liver cancer, etc. Specifically, the anti-cancer mechanism includes regulation of various signaling pathways to induce apoptosis of tumor cells, inhibition of tumor cell proliferation and metastasis, anti-angiogenesis, regulation of immune function, synergistic anti-cancer drugs and regulation of reactive oxygen species levels of tumor cells. Specific anti-cancer mechanisms include regulation of various signaling pathways to induce apoptosis, inhibition of tumor cell proliferation and metastasis, anti-angiogenesis, reversal of epithelial-mesenchymal transition, regulation of immune function, synergism with anti-cancer drugs and regulation of reactive oxygen species levels in tumor cells. This paper integrates the latest cutting-edge research on luteolin and combines it with the prospect of future clinical applications, aiming to explore the mechanism of luteolin exerting different anticancer effects through the regulation of different signaling pathways, so as to provide a practical theoretical basis for the use of luteolin in clinical treatment and hopefully provide some reference for the future research direction of luteolin.

1 December 2024 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
MZMengjie Zhao
Mengjie Zhao
JLJielong Li
Jielong Li
WRWang Rui
Wang Rui
LMLida Mi
Lida Mi
YGYan Gu
Yan Gu
YZYajun Zhang
Yajun Zhang
UBE2C (Ubiquitination-binding enzyme 2C), one of the E2 enzymes encoded in the human genome, is a component of the ubiquitin proteasome system and plays a pivotal role in regulating cell cycle progression. Moreover, UBE2C is highly expressed and may play a pivotal role in both high-incidence and high-mortality malignancies, including lung cancers, breast cancers, and esophageal cancers. UBE2C influences a number of key processes, including cell cycle progression, tumor invasion and metastasis, proliferation, and drug resistance. However, few articles have systematically summarized the role of UBE2C in cancer. The aim of this review is to describe the structure and function of UBE2C, focusing on the current status of UBE2C research in malignant tumors. Furthermore, this review presents the potential of UBE2C as a new therapeutic target and a diagnostic and prognostic biomarker. Finally, future research directions for UBE2C are proposed. It is of great value to explore the mechanism of action of UBE2C in the tumor microenvironment (TME). A comprehensive and coherent comprehension of UBE2C will undoubtedly facilitate its transition from fundamental research to clinical applications.

31 December 2024 in Heliyon
Verified
Journal Article
Open access
WCWeiwei Chen
Weiwei Chen
YJYaya Ji
Yaya Ji
WRWang Rui
Wang Rui
RJRuijie Ji
Ruijie Ji
YLYujian Lin
Yujian Lin
JSJianxiang Song
Jianxiang Song
Research has demonstrated that POU3F4 is integral to various cancers, in addition to its significance in inner ear development, pancreatic differentiation, as well as neural stem cell differentiation. Nevertheless, comprehensive pan-cancer analyses focusing on POU3F4 remain limited. This study aims to assess the prognostic value of POU3F4 in thirty-three cancers and explore its immune-related functions. Based on data from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression (GTE), and Gene Set Cancer Analysis (GSCA), we employed various bioinformatics approaches to investigate the potential carcinogenic effects of POU3F4. Our study encompassed DNA methylation, RNA methylation, tumor mutation burden (TMB), mismatch repair (MMR) genes, microsatellite instability (MSI), the relationship between POU3F4 and prognosis, and immune cell infiltration (ICI) across different tumors. The analysis revealed that POU3F4 expression is typically low in most cancers but is elevated in breast invasive carcinoma, glioblastoma multiforme (GBM), liver hepatocellular carcinoma, and thyroid carcinoma, with the highest levels in GBM. Additionally, POU3F4 expression correlates with cancer prognosis, either positively or negatively. The expression of POU3F4 demonstrated significant associations with MSI in four cancers and TMB in six cancers. POU3F4 expression was significantly linked to DNA methylation in 13 cancer types and RNA methylation in most cancers. It also correlated with the tumor immune microenvironment, immune-related genes, immune checkpoint inhibitors, and drug resistance in various cancers. In vitro experiments demonstrated that POU3F4 enhances cell viability, proliferation, and migration in GBM. Our findings indicate that, given its critical role in carcinogenesis and tumor immunity, POU3F4 serves as a prognostic marker in diverse malignancies.

1 September 2024 in Protein & Peptide Letters
Verified
Journal Article
Closed access
PDF file
WZWeisong Zhang
Weisong Zhang
WRWang Rui
Wang Rui
ZYZhongquan Yi
Zhongquan Yi
RGRongqi Guo
Rongqi Guo
YLYangyang Li
Yangyang Li
SXSong Jian Xiang
Song Jian Xiang
The SCG5 gene has been demonstrated to play an essential role in the development and progression of a range of malignant neoplasms. The regulation of SCG5 expression involves multiple biological pathways. According to relevant studies, SCG5 is differentially expressed in different cancers, and its up- or down-regulation may even affect tumour growth, invasion, and migration, which caught our attention. Therefore, we summarise the regulatory roles played by the SCG5 gene in a variety of cancers and the biological regulatory mechanisms associated with its possible promotion or inhibition of tumour biological behavior, to further explore the potential of SCG5 as a new tumour marker and hopefully provide theoretical guidance for subsequent disease research and treatment.

1 October 2023 in Protein & Peptide Letters
Verified
Journal Article
Closed access
PDF file
WRWang Rui
Wang Rui
XLXia Li
Xia Li
YLYangyang Li
Yangyang Li
MZMengjie Zhao
Mengjie Zhao
LMLida Mi
Lida Mi
SXSong Jian Xiang
Song Jian Xiang
Estrogen plays a key role in the development and progression of many malignant tumours, and the regulation of estrogen levels involves several metabolic pathways. Among these pathways, estrogen sulfotransferase (SULT1E1) is the enzyme with the most affinity for estrogen and is primarily responsible for catalysing the metabolic reaction of estrogen sulphation. Relevant studies have shown significant differences in the expression of SULT1E1 in different malignant tumours, suggesting that SULT1E1 plays a dual role in malignant tumours, both inhibiting the growth of malignant tumours and promoting their development. In addition, the expression level of SULT1E1 may be regulated by a variety of factors, which in turn affect the growth and therapeutic effects of malignant tumours. The aim of this paper is to review the mechanism of action of SULT1E1 in malignant tumours and the mechanisms that are regulated, in order to provide potential targets for the treatment of malignant tumour patients in the future and theoretical support for the realisation of more personalised and effective therapeutic regimens.

1 July 2025 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HWHao Wang
Hao Wang
ZYZhongquan Yi
Zhongquan Yi
SYSong Yan
Song Yan
YWYihao Wang
Yihao Wang
WZWeisong Zhang
Weisong Zhang
SXSong Jian Xiang
Song Jian Xiang
ORMDL proteins (ORMDL1, ORMDL2, ORMDL3) are transmembrane proteins in the endoplasmic reticulum (ER) that regulate sphingolipid metabolism, maintain ER homeostasis, and modulate cellular stress responses. They influence cell proliferation, apoptosis, and metabolic balance. Recent studies have highlighted the altered expression and function of ORMDL proteins in various tumors, including breast cancer, DLBCL, colorectal cancer, and lung cancer. ORMDLs negatively regulate serine palmitoyltransferase (SPT), affecting ceramide and sphingolipid metabolism, which plays a key role in tumor cell proliferation, invasiveness, and resistance to therapy. The dysregulation of ORMDL expression may disrupt sphingolipid metabolism, trigger ER stress, and impair autophagy. Investigating ORMDL functions in cancer could lead to novel insights into tumor development and progression. ORMDL expression may serve as a potential biomarker for cancer diagnosis, prognosis, and therapeutic response prediction. Targeting ORMDL or its metabolic networks offers promising strategies for cancer therapy. Although research on ORMDLs is still in its early stages, further studies are needed to explore their roles in the tumor microenvironment, interactions with the immune system, and applications in personalized medicine. A deeper understanding of ORMDL proteins will enhance tumor diagnosis, treatment, and the development of new therapeutic approaches.